Today: 3 July 2026

South32 share price slides as silver sinks again, with earnings next up

South32 share price slides as silver sinks again, with earnings next up

Sydney, Feb 5, 2026, 17:25 AEDT — Markets have closed. Shares of South32 Ltd dropped roughly 4% on Thursday, closing at A$4.60 after retreating from gains made the previous day. The slide in silver weighed on the stock’s momentum late in the session. Throughout the day, the price fluctuated between A$4.51 and A$4.66, according to market data.
IDBI Bank shares rally again as privatisation bid deadline hits; analyst flags ₹130 target

IDBI Bank shares rally again as privatisation bid deadline hits; analyst flags ₹130 target

IDBI Bank shares pushed higher Thursday, hitting a peak of 113.50 rupees before pulling back slightly to trade around 111.57 rupees by 10:30 a.m., up about 2%. This came despite the Nifty 50 falling 0.5%. The stock has climbed nearly 13% this February, boosted by the Union Budget’s 80,000-crore-rupee disinvestment target. Drumil Vithlani, a technical analyst at Bonanza, noted that breaking above 110 rupees “can further accelerate upside momentum,” eyeing a range of 125–130 rupees. The rally shifts focus onto a long-awaited sale New Delhi has framed as a key test of its push to trim state holdings and attract private investors. For traders, it’s a straightforward calendar play: deadlines draw eyes, even if the results remain uncertain.
5 February 2026
WiseTech Global share price slides again as AI jitters keep hammering ASX software stocks

WiseTech Global share price slides again as AI jitters keep hammering ASX software stocks

SYDNEY, Feb 5, 2026, 16:49 AEDT — Market closed Shares of WiseTech Global Ltd fell 2.6% to close at A$49.92 on Thursday, deepening a recent slide that’s wiped out roughly 13% over the past two sessions. The stock touched a 52-week low of A$47.69 during the day. Trading volume jumped to around 4.08 million shares, up from about 2.42 million on Wednesday, according to Investing.com data.
Bitcoin slides under $71,000 as AI tech rout spills into crypto, stoking fresh selloff

Bitcoin slides under $71,000 as AI tech rout spills into crypto, stoking fresh selloff

Bitcoin slipped below $71,000 in Asian hours on Thursday as a renewed slide in global technology stocks bled into crypto markets, cutting short hopes that last week’s violent swings were settling down. The world’s largest token fell as much as 7.5% over the past 24 hours and touched lows near $70,700 before paring some losses, CoinDesk data showed. https://news.futunn.com/post/68459830/bitcoin-slips-below-71000-as-ai-driven-tech-rout The move matters now because crypto has been trading like a turbo-charged version of the equity risk trade again — falling when tech falls, and falling faster. After a week of whipsaws, some traders had been leaning on the idea that panic selling was largely done.
Deere stock price jumps 4% to a fresh 52-week high — what to watch before DE earnings

Deere stock price jumps 4% to a fresh 52-week high — what to watch before DE earnings

New York, February 4, 2026, 21:20 — The market has closed. Deere & Co shares climbed 4.1% to close at $567.26 on Wednesday, hitting a new 52-week high and marking their third consecutive session of gains. The stock fluctuated between $545.01 and $571.30 during the day, with roughly 3.2 million shares traded as the Dow advanced while the S&P 500 declined.

Stock Market Today

  • AbbVie Jumps 4%, Tops Apogee Buy Price After Earnings Beat
    July 2, 2026, 7:16 PM EDT. AbbVie Inc. finished up 3.99% at $261.07, a new 52-week high. The stock gained nearly $17.8 billion in market cap, putting it well above the $10.9 billion Apogee Therapeutics deal announced June 22. AbbVie closed above targets from RBC Capital, Investing.com and Google Finance. With Q2 earnings set for July 31, the rally puts the spotlight on analyst target hikes. J.P. Morgan and RBC Capital have backed the Apogee buy for its long-term growth, with the company saying the acquisition will add to EPS by 2032. AbbVie outpaced broader markets, which slipped slightly, as investors bet on the drugmaker's deal strategy.
Go toTop